Treatment Options for Hepatitis Delta Virus Infection
- 15 December 2012
- journal article
- research article
- Published by Springer Science and Business Media LLC in Current Infectious Disease Reports
- Vol. 15 (1), 31-38
- https://doi.org/10.1007/s11908-012-0307-z
Abstract
The hepatitis D virus (HDV), the smallest virus known to infect man, causes the most severe form of chronic viral hepatitis, hepatitis delta. It is estimated that about 15 to 20 million people are suffering from chronic HDV infection. HDV is a defective satellite virus depending on the hepatitis B surface antigen (HBsAg) for transmission. Chronic hepatitis delta is associated with a rapid progression of liver fibrosis and a high prevalence of liver cirrhosis, even in younger patients. Immunization against hepatitis B virus (HBV) protects from HDV infection, but there is no specific vaccine against HDV available for HBsAg-positive individuals. Treatment options for hepatitis delta patients are limited. So far, only interferon-alpha has shown an antiviral efficacy against HDV. Recent trials showed sustained virological response rates concerning HDV in 25 %–30 % of patients treated with pegylated interferons. HDV is dominant over HBV in the majority of cases, but HBV DNA-positive subjects should be treated with HBV polymerase inhibitors. Combination therapy of pegylated interferon-alpha and adefovir showed a more pronounced HBsAg decline, but the exact role of combination therapies in hepatitis delta requires further investigation. Alternative future treatment strategies may include prenylation inhibitors and HBV entry inhibitors, which are in early clinical development.Keywords
This publication has 66 references indexed in Scilit:
- HBeAg‐positive hepatitis delta: virological patterns and clinical long‐term outcomeLiver International, 2012
- Hepatitis B Surface Antigen (Hbsag) Decrease and Serum Interferon-Inducible Protein-10 Levels as Predictive Markers for Hbsag Loss during Treatment with Nucleoside/Nucleotide AnaloguesAntiviral Therapy, 2011
- Hepatitis delta virusThe Lancet, 2011
- Clinical outcome of acute and chronic hepatitis delta over time: a long-term follow-up studyJournal of Viral Hepatitis, 2011
- Clinical and virological outcomes in HIV-infected patients with chronic hepatitis B on long-term nucleos(t)ide analoguesAIDS, 2011
- Replicative and Transcriptional Activities of Hepatitis B Virus in Patients Coinfected with Hepatitis B and Hepatitis Delta VirusesJournal of Virology, 2011
- Prevalence, Correlates, and Viral Dynamics of Hepatitis Delta among Injection Drug UsersThe Journal of Infectious Diseases, 2010
- Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: A systematic reviewJournal of Hepatology, 2010
- Establishment of a Novel Quantitative Hepatitis D Virus (HDV) RNA Assay Using the Cobas TaqMan Platform To Study HDV RNA KineticsJournal of Clinical Microbiology, 2010
- Prevalence and Genetic Diversity of Hepatitis B and Delta Viruses in Pregnant Women in Gabon: Molecular Evidence that Hepatitis Delta Virus Clade 8 Originates from and Is Endemic in Central AfricaJournal of Clinical Microbiology, 2008